Intravenous immunoglobulin (IVIG) replacement therapy, has been standard treatment in patients with Primary Immunodeficiency Diseases (PID). Several studies have shown that subcutaneous immunoglobulin (SCIG) infusions demonstrate similar efficacy and are safe and well tolerated in this population.
The objective of this study was to describe the clinical evolution, side effects and tolerability of SCIG in PID patients in reference hospitals in Guanajuato Sate.
An observational, retrospective and transversal study was conducted. A total of 11 patients with PID, who received SCIG (200MG/KG bi-weekle) at any time of their treatment, were included. The intensity of the pain was measured by Analogical Visual Scale (AVS).
Spectrum of PID was: Specific Antobody Deficiency (54%), hypogammaglobulinemia (27%) and IgG1 deficiency (18%). SCIG was the first option therapy in 2 patients, and as IVIG alternative in 9 These patients were switched to 20% SCIG because persistent infections (44%), IVIG high cost (22%), no secure venous acces (22%) and their own confort (11%). A total of 173 SCIG infusions were analized: These were administrated in abdomen, lumbar area, interescapulovertebral zone and back side of arms. Side effects were reported in 8 patients (5 local reactions and 3 systemic effects). No patients suffered infections and no visits to emergency room were reported. AVS average score was 2.11.
This data confirm that SCIG is a safe (no several side effects) and a well tolerated alternative to IVIG. In our patients, the most tolerated area for the SCIG administration was back side of arms.